Goals!

Discussion in 'Salix' started by anonymous, Apr 12, 2019 at 8:17 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Whoooooooo caaaaaaaaaares!!!!!
     

  2. anonymous

    anonymous Guest

    This is well known to most people who have had any relationship at all to Salix. There is no watch and learn. It is completely expected and nobody will be surprised.
     
  3. anonymous

    anonymous Guest

    It’s a joke to have these kind of goals 10-15% Qtr over Qtr! It’s unreal when Labat and his crew cant even get the damn Data right but who cares go out and sell sell sell, what a freaking joke! They are slowly but surely ruining this place
     
  4. anonymous

    anonymous Guest

    The goaling methodology at the home office is actually really simple.

    They take the new hires, give them all darts and have them throw the darts at a map of territories. Territories hit by a dart get a 15% goal increase.
     
  5. anonymous

    anonymous Guest

    Mine must have hit a bullseye because it’s way more than 15%.
     
  6. anonymous

    anonymous Guest

    So nearly 80% of the sales force is below plan for Xifaxan. More than 70% are below for Plenvu. And only about 15% of the reps are at plan for Trulance. Q2 was a cluster from a goal setting perspective. And then they bend us over with our Q3 goals AGAIN! This sucks.
     
  7. anonymous

    anonymous Guest

    I can attest to the fact that almost all Pharmaceutical companies are now doing this with Quotas. Keep the target moving...Keep the reps guessing and striving for greatness all the while knowing that very few will come close to target. Then blame, blame, blame and start the PIP process. It is simply a move to keep inept management in place while rotating the reps out.
     
  8. anonymous

    anonymous Guest

    Relistor was so bad they finally pulled it from Magnifica. At this point its such a joke of a drug (from a managed care perspective) that even management can't ignore it. A significant 7 drug... Shows exactly how much thought they put into that whole idea. Here's an idea for management, give us something that people can actually AFFORD... Almost $1500 when every competitor is pennies on the dollar to that and they still wonders why it isn't selling?
     
  9. anonymous

    anonymous Guest

    Don’t forget that Valeant tripled the price of the Relistor injectable as soon as they bought Salix and then launched the tablet form at four times the original projected price. Bunch of thieves and hucksters. They killed any chance we had to succeed by jacking the prices of our products through the roof. And all they care about is the commercial patient. Screw the old and indigent. Dipshits don’t realize that many of our target patients also fall into those categories.
     
  10. anonymous

    anonymous Guest

    Relistor is a significant 7 for what it brings in the future- not short term,
    You will see.
    If you are focusing on full retail price of our meds you should probably go to another company- you will lose here. None of my offices who had patients fill Relistor Rx’s paid much more than $25- i just had to focus on a few areas with commercial coverage, but thats pretty typical with any branded drug these days.
     
  11. anonymous

    anonymous Guest

    I believe that they used he same exact formula that they used to set the Q2 goals.
    At least they are consistent.
    When i compared mine to what my actual quota was in Q2 they could have been worse. At least they tacked growth onto our history and not on top of the old goals ( that no one hit)
     
  12. anonymous

    anonymous Guest

    Nothing excuses the fact that we pushed the Relistor injectable to almost $4000 a month. That’s about $130 per day to move your bowels. This company is shady AF.
     
  13. anonymous

    anonymous Guest

    What is happening in the future that makes Relistor such a winner? And isn’t Cycloset also one of the significant 7? How’s that going?
     
  14. anonymous

    anonymous Guest

    Sure, but what script volume is that? I bet it's miniscule... Especially relative to all the competitors. It's not putting up enough numbers to be worth being promoted. You need to get much better commercial, Medicare, and Medicaid coverage to be worth it. It's not a rare disease drug... Doctors don't want to (and most won't) hunt for patients to write it for.. Until something changes they'll continue to write Movatik, Amitiza, or generics.
     
  15. anonymous

    anonymous Guest

    The future means that maybe it will have indications in the future that no longer make it a me too.
     
  16. anonymous

    anonymous Guest

    Let me know where you see that listed in our pipeline...
     
  17. anonymous

    anonymous Guest

    Do you think everything gets listed on the pipeline. This was mentioned on a conference call a while back. Do some research yourself / google it/ look at clinical trials.
     
  18. anonymous

    anonymous Guest

    upcoming new indications:

    market size for Crohn's disease drugs is currently around $4B. Most of the drugs used are biologics, which are expensive and with nasty side effects. An antibiotics-based treatment would be much preferable to those, and cheaper too. Rifaximin is the only antibiotic to have shown convincing efficacy for Crohn's disease in medical studies, both for treating the disease and for maintaining remission after the treatment has been done with another drug. So this is one of the main opportunities with the Xifaxan/Rifaximin pipeline.
     
  19. anonymous

    anonymous Guest

    Every quarter without fail the last set of numbers for the quarter is late. Why o why must they manipulate them so?
     
  20. anonymous

    anonymous Guest

    Hmmmmmmmm